InvestorsHub Logo
Followers 14
Posts 2972
Boards Moderated 0
Alias Born 07/19/2006

Re: haysaw post# 20047

Tuesday, 07/29/2014 4:56:00 PM

Tuesday, July 29, 2014 4:56:00 PM

Post# of 30990
Here is the story from a couple weeks ago involving TRGT cancelling their mid-stage AD study:

Targacept ends Alzheimer's drug trial after mid-stage failure
Reuters

http://finance.yahoo.com/news/targacept-ends-alzheimers-drug-trial-204039165.html

July 14 (Reuters) - Targacept Inc said it was ending a mid-stage trial on its Alzheimer's drug as it did not show superiority over standard medication, sending its shares down as much as 19.8 percent.

The drug, TC-1734, which was being tested against Pfizer Inc's donepezil, had earlier failed another mid-stage trial conducted by partner AstraZeneca Plc.

"Based on (today's) results, we do not intend to invest in further development of TC-1734," Targacept Chief Executive Stephen Hill said.

UK-based AstraZeneca returned rights to the drug in March but the companies continue to co-develop another Alzheimer's drug, AZD1446.

The latest failure marks another setback to Targacept's already thinning pipeline. In September, the company discontinued the development of its schizophrenia drug, TC-5619 after it failed a mid-stage study.

(Reporting By Amrutha Penumudi; Editing by Don Sebastian)

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.